Bora制药公司正在主办2026年台北论坛,通过全球合作和AI驱动的效率促进亚洲生物技术创新。 Bora Pharmaceuticals is sponsoring a 2026 Taipei forum to boost Asian biotech innovation through global collaboration and AI-driven efficiency.

波拉制药公司正在台北主办2026年的“伯克利对话”, 该论坛由台湾伯克利俱乐部(Berkeley Club)和伯克利大学(UC Berkeley)领导人主办, 生物技术领袖、投资者和学者聚集一堂, 讨论推广亚洲生物医学创新。 Bora Pharmaceuticals is sponsoring the 2026 "Berkeley Dialogue" in Taipei, a forum hosted by the Berkeley Club of Taiwan and UC Berkeley leadership, bringing together biotech leaders, investors, and academics to discuss scaling Asian biomedical innovation. 活动的重点是全球协作、AI驱动的效率以及尽早调整发展、质量和制造,以提高可靠性和可扩展性。 The event focuses on global collaboration, AI-driven efficiency, and aligning development, quality, and manufacturing early to improve reliability and scalability. Bora采用双引擎模式,将CDMO和特种药品结合起来,强调它与Therapi AI的伙伴关系,以提高业务可预测性并获取机构知识。 Bora, which operates a dual-engine model combining CDMO and specialty pharmaceuticals, highlights its partnership with Therapi AI to enhance operational predictability and capture institutional knowledge. 该公司将自己定位为亚洲生物技术公司通向全球临床和商业化通道的桥梁。 The company positions itself as a bridge for Asian biotech firms navigating global clinical and commercialization pathways.